Attached files
| file | filename |
|---|---|
| EX-99.3 - EXHIBIT 99.3 - BRAINSTORM CELL THERAPEUTICS INC. | v444376_ex99-3.htm |
| EX-99.2 - EXHIBIT 99.2 - BRAINSTORM CELL THERAPEUTICS INC. | v444376_ex99-2.htm |
| 8-K - FORM 8-K - BRAINSTORM CELL THERAPEUTICS INC. | v444376_8k.htm |
Exhibit 99.1
Brainstorm to Announce Top Line Results from the U.S. Phase 2 Study of
NurOwn in Patients with Amyotrophic Lateral Sclerosis (ALS)
on Monday, July 18
Conference Call and Live Webcast at 10am Eastern Time
HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 14, 2016 — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce results from the recently completed Phase 2 Study of NurOwn® in Patients with ALS on Monday, July 18, 2016. The Company will host a conference call and webcast with slides at 10:00am Eastern Time.
Monday, July 18, 2016 @ 10:00am Eastern Time
| Toll Free: | 888-452-4023 |
| Israel Investors: | 1 80 924 5906 |
| International: | 719-457-1512 |
| Conference ID: | 5455376 |
| Webcast: | http://public.viavid.com/index.php?id=120422 |
Replays, available through August 1, 2016
| Toll Free: | 877-870-5176 |
| International: | 858-384-5517 |
| Conference ID: | 5455376 |
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn®technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn®has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
CONTACTS
Media:
Uri Yablonka, COO
Chief Operating Officer
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com
Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com